Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema

被引：31

作者：

Cohn, Danny M. ^{[1
]}

Viney, Nicholas J. ^{[4
]}

Fijen, Laure M. ^{[1
]}

Schneider, Eugene ^{[4
]}

Alexander, Veronica J. ^{[4
]}

Xia, Shuting ^{[4
]}

Kaeser, Gwendolyn E. ^{[4
]}

Nanavati, Charvi ^{[4
]}

Baker, Brenda F. ^{[4
]}

Geary, Richard S. ^{[4
]}

Levi, Marcel ^{[5
,6
,7
]}

Meijers, Joost C. M. ^{[2
,3
]}

Stroes, Erik S. G. ^{[1
]}

机构：

[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands

[2] Univ Amsterdam, Amsterdam UMC, Dept Expt Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands

[3] Sanquin Res, Dept Mol & Cellular Hemostasis, Amsterdam, Netherlands

[4] Ionis Pharmaceut, Carlsbad, CA USA

[5] Univ Coll London Hosp NHS Fdn Trust, Dept Med, London, England

[6] Univ Coll London Hosp, Natl Inst Hlth Res, Cardiometab Programme, London, England

[7] UCL, Biomed Res Ctr, London, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 13期

关键词：

PLASMA KALLIKREIN; DEFICIENCY;

D O I：

10.1056/NEJMoa1915035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hereditary angioedema is characterized by recurrent and unpredictable episodes of subcutaneous and mucosal swelling that can be life threatening. IONIS-PKK-L-Rx is a ligand-conjugated antisense oligonucleotide designed for receptor-mediated delivery to hepatocytes. In a compassionate-use pilot study, two patients with severe bradykinin-mediated angioedema were initially administered weekly subcutaneous injections of the unconjugated parent drug, IONIS-PKKRx, for 12 to 16 weeks, after which they received IONIS-PKK-L-Rx at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months. Treatment was accompanied by a reduction in the angioedema attack rate.

引用

页码：1242 / 1247

页数：6

共 50 条

[1] Plasma Prekallikrein: its Role in Hereditary Angioedema and Health and Disease
Schmaier, Alvin H.
FRONTIERS IN MEDICINE, 2018, 5
[2] A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
Petersen, Remy S.
Bordone, Laura
Riedl, Marc A.
Tachdjian, Raffi
Craig, Timothy J.
Lumry, William R.
Manning, Michael E.
Bernstein, Jonathan A.
Raasch, Jason
Zuraw, Bruce L.
Deng, Yiwen
Newman, Kenneth B.
Alexander, Veronica J.
Lui, Cindy
Schneider, Eugene
Cohn, Danny M.
ALLERGY, 2024, 79 (03) : 724 - 734
[3] Kallikrein Inhibition for Hereditary Angioedema
Longhurst, Hilary J.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08) : 788 - 789
[4] A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes
Joseph, K.
Bains, S.
Tholanikunnel, B. G.
Bygum, A.
Aabom, A.
Koch, C.
Farkas, H.
Varga, L.
Ghebrehiwet, B.
Kaplan, A. P.
ALLERGY, 2015, 70 (01) : 115 - 119
[5] Hereditary angioedema
Caballero Molina, Teresa
Pedrosa Delgado, Maria
Gomez Traseira, Carmen
MEDICINA CLINICA, 2015, 145 (08): : 356 - 365
[6] Hereditary angioedema: the plasma contact system out of control
De Maat, S.
Hofman, Z. L. M.
Maas, C.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (09) : 1674 - 1685
[7] IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
Ferrone, Jason D.
Bhattacharjee, Gourab
Revenko, Alexey S.
Zanardi, Thomas A.
Warren, Marshelle S.
Derosier, Frederick J.
Viney, Nicholas J.
Pham, Nguyen C.
Kaeser, Gwendolyn E.
Baker, Brenda F.
Schneider, Eugene
Hughes, Steven G.
Monia, Brett P.
MacLeod, A. Robert
NUCLEIC ACID THERAPEUTICS, 2019, 29 (02) : 82 - 91
[8] Pathogenesis and laboratory diagnosis of hereditary angioedema
Zuraw, Bruce L.
Christiansen, Sandra C.
ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (05) : 487 - 492
[9] Diagnosis of hereditary angioedema
Bouillet, Laurence
PRESSE MEDICALE, 2015, 44 (01): : 52 - 56
[10] The Pathophysiology of Hereditary Angioedema
Zuraw, Bruce L.
WORLD ALLERGY ORGANIZATION JOURNAL, 2010, 3 : S25 - S28

← 1 2 3 4 5 →